Risk adjusted net present value: What is the current valuation of Medivir’s Fostroxacitabine Bralpamide Hydrochloride?

Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.

J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer

Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about commercial strategies as he left for a similar job at

March 20, 2024

Asian American doctors, overrepresented in medicine, are largely left out of leadership

For 15 years, orthopedic surgeon Charles S. Day has been working to highlight the striking lack of diversity in his field, publishing studies showing orthopedics

July 26, 2023

Dana-Farber chief Laurie Glimcher set to leave storied cancer center

After eight years, Laurie Glimcher will step down as president and CEO of the Dana-Farber Cancer Institute, Boston’s famed oncology research center. Replacing her on

September 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.